THE-EARTHSHOT-PRIZE
17.9.2021 19:03:10 CEST | Business Wire | Press release
The Earthshot Prize announces today its first-ever shortlist of 15 Finalists, each with a chance of winning £1million to support their innovative environmental solutions to the greatest challenges facing the planet.
Prince William said: "Over half a century ago, President Kennedy’s ‘Moonshot’ programme united millions of people around the goal of reaching the moon. Inspired by this, The Earthshot Prize aims to mobilise collective action around our unique ability to innovate, problem solve and repair our planet.
“I am honoured to introduce the 15 innovators, leaders, and visionaries who are the first ever Finalists for The Earthshot Prize. They are working with the urgency required in this decisive decade for life on Earth and will inspire all of us with their optimism in our ability to rise to the greatest challenges in human history.”
Launched by Prince William and The Royal Foundation in October 2020, The Earthshot Prize is the most prestigious global environment prize in history. Like President John F. Kennedy’s ‘Moonshot’ did almost 60 years ago, the Prize aims to unleash an unprecedented wave of innovation and leadership to tackle our greatest environmental challenges. The Earthshot Prize will be awarded every year for the next decade, discovering a total of 50 Winners.
Five of these 15 Finalists will be awarded The Earthshot Prize and will win £1million in Prize funding for the best solutions of the five Earthshot goals: Protect and Restore Nature; Clean our Air; Revive our Oceans; Build a Waste-free World; and Fix our Climate . The Winners will be announced during an awards ceremony on 17th October from London’s Alexandra Palace, broadcast in the UK on BBC One and globally on Discovery+.
The Earthshot Prize Finalists for 2021 are:
Protect and Restore Nature:
- Pole Pole Foundation, Democratic Republic of Congo
An inspiring community-led model of conservation that protects gorillas and local livelihoods.
- The Republic of Costa Rica
A pioneering scheme paying local citizens to restore natural ecosystems that has led to a revival of the rainforest.
- Restor, Switzerland
A ground-breaking online platform connecting and empowering local conservation projects.
Clean our Air:
- The Blue Map App, China
China’s first public environmental database enabling citizens to hold polluters to account.
- Takachar, India
A pioneering technology to create profitable products from agricultural waste and put a stop to the burning of crops.
- Vinisha Umashankar, India
A 14-year-old innovator and activist who has designed a solar-powered ironing cart with the potential to improve air quality across India.
Revive our Oceans:
- Coral Vita, Bahamas
A truly cutting-edge breakthrough in coral farming that can restore our world’s dying coral reefs.
- Living Seawalls, Australia
Innovative and replicable seawall panels bringing marine life back to coastal sea defences.
- Pristine Seas, USA
An unprecedented global conservation programme protecting 6.5 million square km of the world’s ocean.
Build a Waste-Free World:
- The City of Milan Food Waste Hubs, Italy
A city-wide initiative that has dramatically cut waste while tackling hunger.
- Sanergy, Kenya
A circular sanitation solution that converts human waste into safe products for local farmers.
- WOTA BOX, Japan
A tiny water treatment plant that turns 98% of wastewater into clean water.
Fix our Climate:
- AEM Electrolyser, Thailand/Germany/Italy
An ingenious green hydrogen technology developed to transform how we power our homes and buildings.
- Reeddi Capsules, Nigeria
Solar-powered energy capsules making electricity affordable and accessible in energy-poor communities.
- SOLbazaar, Bangladesh
The world’s first peer-to-peer energy exchange network in a country on the front-line of climate change.
All 15 Finalists will receive support from The Earthshot Prize Global Alliance Members, an unprecedented network of global businesses, who will help scale their solutions for even greater impact.
Of these 15 Finalists, the five Winners will be selected by The Earthshot Prize Council, a diverse team of influential individuals which includes: HRH Prince William, Her Majesty Queen Rania Al Abdullah of Jordan, Sir David Attenborough, Dr Ngozi Okonjo-Iweala, Indra Nooyi, Shakira Mebarak, Christiana Figueres, Luisa Neubauer, Cate Blanchett, Yao Ming, Daniel Alves Da Silva, Ernest Gibson, Hindou Oumarou Ibrahim, Jack Ma, and Naoko Yamazaki.
In the run-up to the prize-giving ceremony on 17 October, BBC and Discovery will release a 5-part documentary series THE EARTHSHOT PRIZE: REPAIRING OUR PLANET, featuring Earthshot Prize Council Members including Prince William, Shakira Mebarak, Daniel Alves Da Silva and Sir David Attenborough.
For more information about the Finalists and The Earthshot Prize, visit: www.earthshotprize.org , email Claire Straw: TEPmedia@freuds.com, download media pack here .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210917005454/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom